Tag Archives: Cervical Cancer

New Possible Cervical Cancer Treatments Focus on Cancer’s Energy Supply

New Possible Cervical Cancer Treatments Focus on Cancer's Energy Supply
New Possible Cervical Cancer Treatments Focus on Cancer’s Energy Supply

A new potential cervical cancer treatment is making waves. After decades of the same, largely unchanged treatment protocol, there may be a new hope on the horizon. A study conducted on mice by the Washington University School of Medicine in St. Louis has uncovered that cervical tumors that don’t respond to radiation are vulnerable to therapies that cut off cancer’s energy supply at the source.

Turning Cervical Cancer ‘Off’
The mice used in the study, implanted with human cervical cancer cells, provided some interesting data. When treated with a combination of radiation and 3 drugs designed to slow tumor metabolism, cancer’s ability to burn glucose and protect itself was shut down, thwarting cancer cell survival attempts.

The Sugar-Zapping Theory
Cancer cells take up glucose in larger amounts than normal tissues. Researchers in the study observed that tumors resisting treatment were those that took up a large deal of glucose prior to radiation therapy. On the hypothesis that sugar strengthens tumor resistance, they decided to delve closer into what would happen if that sugar uptake was inhibited.

Shocking Potential
With glucose eliminated as a food source, cancer cells must scavenge for sustenance. In typical treatment modalities, cancer will rally by hitting the cells’ metabolic pathways in two more ways simultaneously, making tumors vulnerable to their own self-created toxic stew.

Free radical toxicity escalates, eventually devastating the cancer cells. As healthy cells don’t rely on this fuel production pathway, no obvious negative side-effects were revealed. Future studies will explore this cancer treatment’s potential in HPV-induced cervical cancer.

Looking for the latest in cutting-edge cancer treatment methods? Discover the Issels® immunotherapy difference today.

Medicare Coverage for Early Detection of Cancer – What to Know

Medicare Coverage for Early Detection of Cancer - What to Know
Medicare Coverage for Early Detection of Cancer – What to Know

Navigating the ins and outs of Medicare coverage can be a challenge. Here’s what you need to know about this program and how it applies to screenings for early detection of cancer.

Do All Providers Accept Medicare?

• Participating doctors “accept assignments,” meaning they consider the amount received from Medicare along with your co-pay and deductible as payment in full, resulting in fewer out-of-pocket expenses.

• Non-participating doctors don’t always accept Medicare, so you have to pay out-of-pocket. Medicare will reimburse you for the portions they normally cover, but you still incur sizable expenses for the difference.

• Opt-out doctors don’t participate in Medicare at all, making you fully responsible for all charges.

Medicare Coverage for Cancer Screening

• Annual mammograms are covered for women aged 40 and older, while clinical breast exams (CBE) are covered every two years for women at average risk for breast cancer and once a year for those at high risk.

• Women at average risk for cervical cancer are covered for a Pap test and pelvis exam every two years, while women at high risk are covered annually.

• Colorectal screening is covered for people 50 and over based on risk factors and date of last test.

• For prostate screening, men over age 50 are covered 100 percent for an annual PSA blood test and 80 percent for a digital rectal exam (DRE).

Lung cancer screening is covered once a year if you are between 55 and 77 and have a qualifying history of smoking.

State-of-the-Art Cancer Treatment at Issels®

Our personalized cancer treatment programs have helped many of our patients achieve long-term remission. Visit our website for more information.

Big Pharma Roadblocks Hinder Integrative Cancer Treatment

Conventional Medicine is Not the Answer
Conventional Medicine is Not the Answer

One of the things that makes cancer so difficult to treat is its ability to adapt. Recurrence is not uncommon when standard cancer treatment methods, particularly chemotherapy, are used. As explained in our previous post, cancer cells have an uncanny ability to develop a resistance to chemotherapy drugs which can allow cancer to return.

Value of Integrative Treatment

Cancer researchers are finally coming to the conclusion reached decades ago by renowned German cancer specialist Dr. Josef Issels, the founder of Issels Integrative Oncology: Treating cancer effectively requires an integrative approach that combines multiple treatment protocols. Ridding the body of cancer and driving it into long-term remission requires a multi-pronged attack that must be individualized to meet the specific needs of each patient.

Big Pharma Roadblocks

While alternative cancer treatment centers offer numerous beneficial integrative cancer therapies, Western medicine’s current approach to integrative cancer treatment is heavily drug based. Not only is the approach limiting; but, as Dr. Carlos Moreno of Emory University recently criticized on Reuters.com, Big Pharma roadblocks are hindering the development of integrative drug therapies.

Profits vs. Patients

Combining drugs into “cancer cocktails” and treating cancer with drugs approved to treat other conditions has shown early promise. But these approaches require cooperation from drug companies, most of which have so far been unwilling to put patients ahead of profits, Moreno complains.

Issels Puts Patients First

As Moreno points out, cancer patients don’t have time to wait for researchers and drug companies to resolve their differences. Integrative immunotherapy offers an immediate and effective alternative. Issels non-toxic cancer vaccine program is not forced to rely on the largesse of drug companies. Our autologous cancer vaccines are prepared from the patient’s own blood to enhance the body’s natural ability to fight cancer. Visit our website to learn more about integrative immunotherapy.

Precancerous Cells Linked to Higher Cervical Cancer Rates

Cervical Cancer
Cervical Cancer

A new study shows that women who have been treated for precancerous cells on the cervix may be at greater risk of developing vaginal or cervical cancer and may also be more likely to die should there develop either one of those cancers. Researchers recommended that women continue preventative screenings (PAP smears) into their later years.

The Swedish study found that cancer risk among women diagnosed with CIN3 cells increased with age, rising noticeably after age 60 and again after age 75. By age 75, the risk of developing cervical or vaginal cancer increased to more than 1 in 1,000. Cancer risk also increased among women who had been treated for abnormal cervical cells later in life. For example, the study found that the risk of developing cervical or vaginal cancer was five times greater among women who were treated for precancerous cells when they were in their 60s than it was for women treated in their 30s. Cancer fatalities also increased with age.

As explained on the British Medical Journal website and reported in The Guardian: “Women previously diagnosed with and treated for CIN3 were at substantially increased risk of developing and dying from cervical or vaginal cancer when they reached 60. The risk accelerated with further aging.”

Researchers recommended that women diagnosed with precancerous cells on their cervix when they were young continue to follow-up with their physician as they age. In a separate study, British researchers found that continuing regular PAP smears between age 50 and 64 may reduce cervical cancer risk into a woman’s 80s.

“Where a cervical cancer is found through screening it is usually at a very early stage where treatment has a greater chance of success,” Julietta Patnick of Britain’s National Health Service said.